dc.creator | Vejnović, Dubravka | |
dc.creator | Milić, Vera | |
dc.creator | Popović, Branka | |
dc.creator | Damnjanović, Tatjana | |
dc.creator | Maksimović, Nela | |
dc.creator | Bunjevački, Vera | |
dc.creator | Krajinović, Maja | |
dc.creator | Novaković, Ivana | |
dc.creator | Damjanov, Nemanja | |
dc.creator | Jekić, Biljana | |
dc.date.accessioned | 2020-07-13T08:48:00Z | |
dc.date.available | 2020-12-21 | |
dc.date.issued | 2019 | |
dc.identifier.issn | 1742-5255 | |
dc.identifier.uri | https://smile.stomf.bg.ac.rs/handle/123456789/2526 | |
dc.description.abstract | Background: Methotrexate (MTX), a folate analogue, is the most commonly used disease-modifying drug in the treatment of rheumatoid arthritis (RA). However, high interindividual differences in drug response are present among RA patients.Research design and methods: In a group of 234 RA patients treated with MTX, we investigated whether rs1650697 polymorphism in DHFR gene may have an impact on MTX efficacy and/or adverse drug effects (ADEs). Relative DAS28 values (rDAS28) were used for the estimation of MTX therapy and all ADEs were recorded. Patients were genotyped for selected polymorphism by real-time PCR method. Results: According to the European League Against Rheumatism criteria after 6 months of MTX therapy, 196 patients (83.8%) were classified as responders (25 (10.7%) were good and 171 (73.1%) were moderate) and 38 patients (16.2%) as nonresponders. ADEs were observed in 55 patients (23.5%). Conclusions: Our results showed that the presence of T allele might be protective against MTX hepatotoxicity measured by transaminase levels (p = 0.05). Furthermore, among patients who also received low-dose corticosteroids, we have found a lower rDAS value in patients with CC genotype (p = 0.039). | en |
dc.publisher | Taylor & Francis Ltd, Abingdon | |
dc.relation | info:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175091/RS// | |
dc.rights | embargoedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.source | Expert Opinion on Drug Metabolism & Toxicology | |
dc.subject | DHFR | en |
dc.subject | genetic polymorphism | en |
dc.subject | methotrexate | en |
dc.subject | pharmacogenetics | en |
dc.subject | rheumatoid arthritis | en |
dc.subject | toxicity | en |
dc.title | Association of C35T polymorphism in dihydrofolate reductase gene with toxicity of methotrexate in rheumatoid arthritis patients | en |
dc.type | article | |
dc.rights.license | BY-NC-ND | |
dcterms.abstract | Дамњановић, Татјана; Вејновић, Дубравка; Милић, Вера; Поповић, Бранка; Максимовић, Нела; Буњевачки, Вера; Крајиновић, Маја; Новаковић, Ивана; Дамјанов, Немања; Јекић, Биљана; | |
dc.citation.volume | 15 | |
dc.citation.issue | 3 | |
dc.citation.spage | 253 | |
dc.citation.epage | 257 | |
dc.citation.other | 15(3): 253-257 | |
dc.citation.rank | M21 | |
dc.description.other | This is the peer-reviewed version of the article: Vejnović, D.; Milić, V.; Popović, B.; Damnjanović, T.; Maksimović, N.; Bunjevački, V.; Krajinović, M.; Novaković, I.; Damjanov, N.; Jekić, B. Association of C35T Polymorphism in Dihydrofolate Reductase Gene with Toxicity of Methotrexate in Rheumatoid Arthritis Patients. Expert Opinion on Drug Metabolism & Toxicology 2019, 15 (3), 253–257. [https://doi.org/10.1080/17425255.2019.1563594] | |
dc.identifier.wos | 000458880400007 | |
dc.identifier.doi | 10.1080/17425255.2019.1563594 | |
dc.identifier.pmid | 30583708 | |
dc.identifier.scopus | 2-s2.0-85059575374 | |
dc.identifier.fulltext | https://smile.stomf.bg.ac.rs/bitstream/id/5271/Association_of_C35T_acc_2019.pdf | |
dc.type.version | acceptedVersion | |